8712 Stäfa, ch
+41 (58) 92833-47
Sonova posts strong growth in sales and increase in operating profit for the first half of 2010/11
-The Sonova Group increased sales in the first six months of financial year 2010/11 by 17.2% in Swiss francs to CHF 832 million, with a negative currency effect of 2.8%. Sales growth in local currencies was 20.0%.
-Organic sales growth of 8.2% in local currencies exceeded the market growth of the hearing instrument industry, estimated at 4-5%.
-Sonova generated an additional 11.8% sales growth from acquisitions. The integration of the newly acquired companies Advanced Bionics and InSound Medical is on track.
-Group EBITA increased by 5.3% to CHF 204 million, corresponding to an EBITA margin of 24.5%. This includes the planned investments for the strategic acquisitions and projects and a negative currency effect of around 70 basis points.
- Cash-based basic earnings per share increased to CHF 2.676.
-81% of total sales were achieved with products which were launched within the past two years. This highlights the success of the entire Phonak portfolio based on the CORE platform.
-EUHA October 2010: Sonova expands its technology leadership by launching a host of new, innovative products based on the new Spice platform.
-The Sonova Group continues to expect organic sales growth of 8-10% in local currencies and an EBITA margin of around 26% for financial year 2010/11.
This Media Release may contain forward-looking statements which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside the company's control.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.